Immunocore Expands Senior Management
This article was originally published in Scrip
Immunocore Ltd. a company focused on treating cancer, viral infections and autoimmune diseases, has appointed James Sandy chief development officer and Julian Hirst director of corporate finance. Both individuals bring over 25 years' of experience from various industries to the company, with Sandy most recently being chief development officer at Creabilis Ltd. Prior to this, he held numerous positions at Pfizer Inc., including head of EU and Asian development operations, development team leader within the gastrointestinal therapeutic area and oncology therapeutic area head, EU. Hirst was previously vice chair and head of corporate finance at Panmure Gordon, head of EU technology and a managing director at UBS and head of EU media at Morgan Stanley.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.